Long-term outcomes with cobalt-chromium bare-metal vs. drug-eluting stents: the REgistro regionale AngiopLastiche dell'Emilia-Romagna registry
Authors:
- Paolo OrtolaniPOPaolo Ortolani
- Paolo GuastarobaPGPaolo Guastaroba
- Paolo MarzaroliPMPaolo Marzaroli
- Mila MenozziMMMila Menozzi
- Paolo MagnavacchiPMPaolo Magnavacchi
- Elisabetta VaraniEVElisabetta Varani
- Luigi VignaliLVLuigi Vignali
- Gianluca CampoGianluca Campo
- Antonio MarzocchiAMAntonio Marzocchi
- 1 February 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 12 (2) , 102-109
Abstract
To compare the long-term efficacy of cobalt-chromium bare-metal stents (CCSs) with that of first-generation drug-eluting stents (DESs) in patients within a large real-world multicentre registry. The incidence of major adverse cardiac events [death, acute myocardial infarction, and target-vessel revascularization (TVR)] and angiographic stent thrombosis were assessed in consecutive patients undergoing percutaneous coronary intervention with CCS (n = 1103) or DES (n = 5195) during 2-year follow-up. Propensity score-adjusted outcomes, overall and in patients with low (≤ 10%), intermediate (10-15%), and high (>15%) 1-year restenosis risk, were estimated. DES-treated patients had significantly higher rates of diabetes, longer lesions, and smaller vessel diameters than CCS-treated patients (all P < 0.0001). However, CCS patients were older and presented a higher rate of hypertension, previous myocardial infarction, and heart failure (all P < 0.01). At 2 years, adjusted rates of myocardial infarction, death, and cumulative-stent thrombosis were similar for DES and CCS. DES provided statistically significant (P < 0.01) reductions in TVR and adjusted major adverse cardiac event rates (9.7 and 17.2%, respectively) compared with CCS (13.2 and 21.2%, respectively). In patients at highest and intermediate risk of restenosis, adjusted TVR rates were significantly (P < 0.01) lower with DES (12.2 and 8.9%, respectively) than CCS (19.9 and 17.1%, respectively), but rates were similar in low-risk patients. DESs were more effective than CCSs in lowering TVR rates in patients with an intermediate-high baseline restenosis risk.Keywords
This publication has 32 references indexed in Scilit:
- Three-Year Survival Following Multivessel Percutaneous Coronary Intervention With Bare-Metal or Drug-Eluting Stents in Unselected PatientsThe American Journal of Cardiology, 2009
- Long-Term Safety and Efficacy of Drug-Eluting StentsCirculation, 2007
- A Cause for ConcernCirculation, 2007
- Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in SwedenNew England Journal of Medicine, 2007
- Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary StentsNew England Journal of Medicine, 2007
- A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal StentsNew England Journal of Medicine, 2007
- Late Thrombosis of Drug-Eluting Stents: A Meta-Analysis of Randomized Clinical TrialsThe American Journal of Medicine, 2006
- Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting StentsJACC, 2006
- Usefulness of a cobalt chromium coronary stent alloyThe American Journal of Cardiology, 2003
- Intracoronary Stenting and Angiographic ResultsCirculation, 2001